Summary
Seven monoclonal antibodies (mAbs) reactive with ganglioside II3(NeuAc)2-LacCer (GD3) were generated; four of these mAbs (DMAb-21, DMAb-22, DMAb-23, and DMAb-24) by immunizing mice with GD3 adsorbed to Salmonella minnesota and the remaining three (DMAb-7, DMAb-8, and DMAb-17) with melanoma line SK-MEL 28, which contains 1.4 nmol sialic acid of GD3 per mg protein. The specificities of the mAbs were defined by high-performance thin-layer chromatography (HPTLC) immunostain and solid-phase radioimmunoassay (SP-RIA) with a panel of purified gangliosides. DMAb-7 and DMAb-8 reacted with GD3, IV3(NeuAc)2nLcOse4Cer(3′,8′-LD1), and very weakly with IV3(NeuAc)2II3NeuAc-GgOse4Cer (GTla), but not with II3NeuAc-LacCer (GM3), II3NeuAcGgOse3Cer(GM2), II3NeuAc-GgOse4Cer(GM1), II3NeuAc, IV3NeuAcGgOse4Cer (GD1a), II3(NeuAc)2GgOse3(GD2), II3(NeuAc)2GgOse4Cer (GD1b), IV3NeuAcII3(NeuAc)2, GgOse4Cer(GT1b), suggesting the binding epitope to be a terminal tetrasaccharide NeuAcα2-8NeuAcα2-3Galβ1-4(Glc or GlcNAc). DMAb-7 and DMAb-8 were used to investigate the expression of GD3 on cultured human tumor cells of neuroectodermal origin. Thirteen of 19 gliomas, 3 of 5 medulloblastomas, 5 of 5 neuroblastomas, 2 of 2 melanomas, and 1 of 3 teratomas were shown to react with DMAb-8 and/or DMAb-7 by cell surface-RIA (CS-RIA) and immunofluorescence (IF) assays. HPTLC and densitometric analysis confirmed these results, as positive immunostains in the GD3 region were obtained with oligoganglioside fractions from 9 glioma, 1 medulloblastoma, 2 neuroblastoma, 1 melanoma, and 1 teratoma cell line. Glioma cell line U-105 MG and medulloblastoma cell line Daoy contain GD3 as shown by HPTLC immunostain analysis of extracts, although GD3 was undetectable on the cell surface as determined by CS-RIA and IF. There was no detectable GD3 found in gangliosides isolated from cell lines U-373 MG, D-54 MG, TE-671, and PA-1, which were negative for both DMAb-7 and DMAb-8 by CS-RIA and IF assay. Our results provide evidence that GD3 is expressed extensively with significant quantitative heterogeneity on cultured human neuroectodermal tumor cells including glioma, medulloblastoma, neuroblastoma, and melanoma.
Similar content being viewed by others
References
Berra B, Gaini SM, Riboni L (1985) Correlation between ganglioside distribution and histological grading of human astrocytomas. Int J Cancer 36:363–366
Bigner DD, Bigner SH, Pontén J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201–229
Bigner SH, Mark J, Bigner DD (1987) Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro. Cancer Genet Cytogenet 24:163–176
Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81:5767–5771
Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA (1985) Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 82:5155–5159
Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46:5112–5118
Cheung NKV, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430–1440
Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA 77:6114–6118
Dippold WG, Knuth A, Büschenfelde KHM (1984) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44:806–810
Dippold WG, Dienes HP, Knuth A, Büschenfelde KHM (1985) Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 45:3699–3705
Dohi T, Nores G, Hakomori S (1988) An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res 48:5680–5685
Eto Y, Shinoda S (1982) Gangliosides and neutral glycosphingolipids in human brain tumors: specificity and their significance. Adv Exp Med Biol 152:279–290
Fredman P, Holst HV, Collins VP, Ammar A, Dellheden B, Wahren B, Granholm L, Svennerholm L (1986) Potential ganglioside antigens associated with human gliomas. Neurol Res 8:123–126
Galanos C, Lüderitz O, Westphal O (1971) Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem 24:116–122
Hakomori S (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45:2405–2414
Hakomori S, Kannagi R (1983) Glycosphingolipids as tumor-associated and differentiation markers. JNCI 71:231–251
He X, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD (1989) Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48:48–68
Hellström I, Brankovan V, Hellström KE (1985) Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82:1499–1502
Hersey P, Jamal O, Henderson C, Zardawi I, D'Alessandro G (1988) Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int J Cancer 41:336–343
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242–1246
IUPAC-IUB Commission on Biochemical Nomenclature (1977) The nomenclature of lipids. Eur J Biochem 79:11–21
Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257:14365–14369
Månsson J-E, Fredman P, Bigner DD, Molin K, Rosengren B, Friedman HS, Svennerholm L (1986) Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell line. FEBS 201:109–113
Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098–1104
Natoli EJ, Livingston PO, Pukel CS, Lloyd KO, Wiegandt H, Szalay J, Oettgen HF, Old LJ (1986) A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res 46:4116–4120
Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ (1982) GD3, a prominent ganglioside of human melanoma, detection and characterization by mouse monoclonal antibody. J Exp Med 155:1133–1147
Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissue and sera of neuroblastoma patients. Cancer Res 44:5914–5920
Svennerholm L (1957) Quantitative estimation of sialic acids. II. a colorimetric resorcinol-hydrochloride acid method. Biochim Biophs Acta 24:604–611
Svennerholm L (1963) Chromatographic separation of human brain gangliosides. J Neurochem 10:613–623
Svennerholm L, Fredman P (1980) A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta 617:97–109
Traylor TD, Hogan EL (1980) Gangliosides of human cerebral astrocytomas. J Neurochem 34:126–131
Tsuchida T, Ravindranath MH, Saxton RE, Irie RF (1987) Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res 47:1278–1281
Wikstrand CJ, Bigner DD (1982) Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. Cancer Res 42:267–274
Wikstrand CJ, Mahaley MS, Bigner DD (1977) Surface antigenic characteristics of human glial brain tumor cells. Cancer Res 37:4267–4275
Wikstrand CJ, Mclendon RE, Bullard DE, Fredman P, Svennerholm L, Bigner DD (1986) Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. Cancer Res 46:5933–5940
Wu ZL, Schwartz E, Seeger R, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46:440–443
Yeh MY, Hellström I, Abe K, Hakomori S, Hellström KE (1982) Cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas. Int J Cancer 29:269–275
Yohe HC, Macala LJ, Yu RK (1982) In vitro biosynthesis of the tetrasialoganglioside GQ1b. J Biol Chem 257:249–252
Author information
Authors and Affiliations
Additional information
Supported by NIH grants R37 CA11898, NS 20023, and CA32672 and by grants from the Swedish Medical Research Council (project no. 03X-627), Swedish Cancer Society (project no. 2260-B88-01X) and the National Swedish Board for Technical Development (project no. 84-4667)
Rights and permissions
About this article
Cite this article
He, X., Wikstrand, C.J., Fredman, P. et al. GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathol 79, 317–325 (1989). https://doi.org/10.1007/BF00294668
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00294668